Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Multidisciplinary Approach to Patient with Malignant Melanoma

Author(s): Giuseppina Della Vittoria Scarpati, Celeste Fusciello, Francesco Sabbatino, Soldano Ferrone, Francesco Caponigro, Francesco Perri, Chiara Carlomagno and Stefano Pepe

Volume 13, Issue 6, 2013

Page: [887 - 900] Pages: 14

DOI: 10.2174/18715206113139990079

Price: $65

conference banner
Abstract

The incidence of melanoma is rapidly increasing worldwide and the prognosis of patients with metastatic disease is still poor, with a median survival of 8–9 months and a 3-year overall survival (OS) rate less than 15% [1,2].

A complete surgical excision is the main treatment for primary cutaneous melanoma [3], but controversies about the extension of excision margins still remain [4].

Sentinel lymph node biopsy (SLNB) provides important prognostic and staging data by the identification of regional node-negative patients who would not benefit from a complete nodal dissection. However, there is no consensus in the definition of melanoma thickness to enforce the execution of the SLNB [5].

To date, Interferon-α (IFN-α)is the only approved adjuvant treatment after surgical excision of high-risk melanoma, but its indication remains still controversial [2,6].

Keywords: Melanoma, immunotherapy, B-RAF inibithors, chemotherapy.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy